HighGravityDataInsulet — Feb 20, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-25-000006
Showing in the filing
Total revenue growth (GAAP)
“21% - 24%”
Period
Q1 FY2025
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 21
Total Omnipod Revenue Growth (Constant Curre… for FY2025
“17% to 21%”
U.S. Omnipod Revenue Growth (Constant Curren… for FY2025
“16% to 20%”
International Omnipod Revenue Growth (Consta… for FY2025
“22% to 26%”
Drug Delivery Revenue Growth (Constant Curre… for FY2025
“(55)% to (45)%”
Total revenue growth for FY2025
“22% to 25%”
Total Omnipod revenue growth for FY2025
“23% to 26%”
Total Omnipod revenue growth (constant curre… for Q1 FY2025
“23% to 26%”
U.S. Omnipod revenue growth for FY2025
“21% to 24%”
U.S. Omnipod revenue growth (constant curren… for Q1 FY2025
“21% to 24%”
International Omnipod revenue growth for FY2025
“28% to 31%”
International Omnipod revenue growth (consta… for Q1 FY2025
“28% to 31%”
Drug Delivery revenue growth for FY2025
“(10)% to (5)%”
Drug Delivery revenue growth (constant curre… for Q1 FY2025
“(10)% to (5)%”
Gross Margin for FY2025
“approximately 70.5%”
Operating margin for FY2025
“approximately 16.5%”
International Omnipod revenue growth (GAAP) for FY2025
“19% - 23%”
Total revenue growth (GAAP) for FY2025
“15% - 19%”
Total revenue growth (GAAP) for Q1 FY2025
“21% - 24%”
International Omnipod revenue growth (GAAP) for Q1 FY2025
“24% - 27%”
Total Omnipod revenue growth (GAAP) for Q1 FY2025
“22% - 25%”
Total revenue growth (Constant Currency) for Q1 FY2025
“22% - 25%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Omnipod 16% - 20% —% 16% - 20% International Omnipod 19% - 23% (3)% 22% - 26% Total Omnipod 16% - 20% (1)% 17% - 21% Drug Delivery (55)% - (45)% —% (55)% - (45)% Total 15% - 19% (1)% 16% - 20% Three Months Ending March 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 21% - 24% —% 21% - 24% International Omnipod 24% - 27% (4)% 28% - 31% Total Omnipod 22% - 25% (1)% 23% - 26% Drug Delivery (10)% - (5)% —% (10)% - (5)% Total 21% - 24% (1)% 22% - 25% 13
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.